Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 3, 2002, Pages 265-275

  Xie, Rujia ^a,b   Mathijssen, Ron H J ^a,b   Sparreboom, Alex ^a,b   Verweij, Jaap ^a,b   Karlsson, Mats O ^a,b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; CIPROFLOXACIN; CISPLATIN; IRINOTECAN; LOPERAMIDE; TIPIFARNIB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; CHI-SQUARE DISTRIBUTION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCURONATES; HUMANS; MALE; MIDDLE AGED;

EID: 0036738120     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.126741     Document Type: Article

References (31)

1. Irinotecan in the treatment of colorectal cancer: Clinical overview
2. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
3. Genetic predisposition to the metabolism of irinotecan (CPT-11)
4. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
5. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
6. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
7. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
8. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors
9. Clinical pharmacology of camptothecins
10. CPT-11: Population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer
11. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
12. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
13. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38
14. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors
15. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
16. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
17. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors
18. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
19. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer
20. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
21. Building population pharmacokinetic-pharmacodynamic models; I: Models for covariate effects
22. Xpose - An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
23. Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships
24. Clinical pharmacokinetics of irinotecan given in combination with the farnesyl transferase inhibitor Zarnestra
25. Clinical pharmacokinetics of irinotecan
26. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients
27. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
28. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
29. Polymorphisms of UDP-glucuronosyl-transferase and pharmacokinetics of irinotecan
30. Irinotecan (CPT-11) disposition in relation to single-nucleotide polymorphisms (SNPs) of ABC transporters and drug-metabolizing enzymes